← Back to Blog
Medical Tourism

Microvascular Angina and INOCA: Getting an IMR Second Opinion in China

OriEast Editorial Team•2026-11-22

Quick Answer

Use this page to quickly understand what kinds of topics we cover, who the content is most useful for, and where to go next.

Main topics
Medical Tourism
Best for
China's NMPA has cleared an angiography-based IMR calculation software, giving patients with chest pain and "normal" angiograms a concrete test to ask about when seeking a cardiology second opinion in China.
Best next step
Read Patient Guides

Need help applying this to your own case?

OriEast can help turn what you learned here into the right next step for hospital choice, records preparation, or travel planning.

How OriEast helps

We help international patients move from reading and research to real medical coordination in China.

  • ✓Clarify whether this topic is relevant to your case or travel plan
  • ✓Shortlist the right hospital, service, or specialist pathway
  • ✓Review records and reduce planning mistakes before booking
  • ✓Support hospital coordination, travel timing, and next-step questions

Your records are only shared as needed to coordinate planning and specialist review.

Chest pain that behaves like angina, an angiogram reported as "clean", and a doctor who cannot explain the symptoms — this is where the diagnostic trail often dead-ends for patients with microvascular angina, part of a broader picture called INOCA (ischaemia with no obstructive coronary arteries). On 19 November 2026 China's National Medical Products Administration (NMPA) published a device approval that gives this group something unusually concrete to ask about: coronary angiography microcirculatory resistance index (IMR) calculation software, cleared through the country's special review procedure for innovative medical devices. For international patients considering a cardiology second opinion in China, that turns a vague question — could this be my microcirculation? — into one a catheterisation lab can answer yes or no to.

It is worth being precise about what this is, because the most common disappointment in medical travel comes from overstated expectations. IMR is a diagnostic measurement, not a therapy. What follows is how the test works, what the Chinese approval actually covers, and how to build a second-opinion plan around it.

When the angiogram is normal but the symptoms are not

A coronary angiogram pictures the large, epicardial arteries on the surface of the heart. It is an excellent test for blockages in those vessels and a poor one for everything else. The microcirculation — the network of tiny arterioles that actually regulates blood flow into the heart muscle — is too small to resolve on X-ray angiography at all. When those vessels fail to relax properly, or constrict inappropriately, the result is genuine ischaemia with a genuinely unobstructed angiogram.

The symptom pattern patients describe is usually exertional chest pressure or tightness, sometimes breathlessness, fatigue, or discomfort at rest, often with the traditional risk factors — high blood pressure, high cholesterol, diabetes, smoking history — already present. It is frequently reported in women, whose symptoms are more often atypical and therefore more often attributed elsewhere. A "your arteries are fine, it is anxiety" conversation followed by years of unchanged limitations is not a rare outcome; it is, in fact, the reason INOCA is now recognised as its own clinical entity with its own management, rather than a diagnosis of exclusion.

The catch has always been measurement. Confirming microvascular dysfunction requires either invasive physiology performed during catheterisation or advanced non-invasive imaging, and many labs simply do not run those protocols routinely. That is the gap the newly cleared software sits in.

What the November 2026 NMPA approval says — and does not say

From the regulator's own announcement, the verifiable facts are limited and specific:

  • The approval information was published on 19 November 2026 in the NMPA's innovative medical device column.
  • The product is described as coronary angiography microcirculatory resistance index (IMR) calculation software, reported in coverage of the announcement under the trade name AccuIMR.
  • The developer named in the record is the Hangzhou-based company 杭州脉流科技.
  • Its intended purpose is assessing coronary microcirculatory function in adults from coronary angiography images.
  • It is a software product cleared via the special review pathway for innovative medical devices.

Read the NMPA entry before you build a plan on it, and note what is absent: no clinical outcome claims, no price, no list of adopting hospitals, and no implication that this clears anything for sale outside mainland China. A Chinese regulatory approval is meaningful to you as a patient precisely because it means a legally cleared quantitative tool exists inside the system you would be travelling to — not because it has changed guidelines in London, Toronto or Dubai.

IMR, FFR and the other options: what each one actually answers

What you can ask the lab forWhat it measuresWhat it can settleLimits to know up front
Standard angiography aloneLumen narrowing in large arteriesWhether a stent or bypass is relevantBlind to microvascular function; a normal result does not exclude ischaemia
FFR (fractional flow reserve)Pressure drop across a narrowing using a pressure wireWhether a visible intermediate lesion is haemodynamically significantSays little about the small vessels when there is no epicardial blockage to test
IMR, classic pressure-wire methodResistance in the microcirculation, measured during maximal hyperaemiaWhether microvascular resistance is objectively elevatedRequires a sensor wire and a vasodilator agent; availability depends on the lab's protocol
IMR derived from angiography imagesModelled microvascular resistance computed from the X-ray sequence itselfQuantification without some of the extra hardware stepsDepends on image quality and on the cleared software being installed and validated locally
Acetylcholine provocationWhether vessels spasm abnormallyVasospastic angina specificallyDifferent mechanism from microvascular resistance; not the same test
Cardiac PET or stress CMRMyocardial blood flow reserve non-invasivelyEvidence of ischaemia without catheterisationAccess and tracer availability vary widely between countries

A practical consequence: when you ask for "IMR testing", clarify which method the department uses and whether the newly cleared image-based software is part of that workflow. Those are different conversations with different scheduling implications, and the distinction is exactly the kind of detail a second-opinion coordinator can pin down for you in advance rather than at the airport.

How to put the request to a Chinese cardiology department

Cath labs are not marketing departments, and a general enquiry form will not reach the right person. Send the clinical question directly to the interventional or structural cardiology team, together with your records. Four questions do most of the work:

  1. Does the department perform invasive coronary physiology, specifically IMR, as part of a diagnostic catheterisation for suspected INOCA?
  2. Is an NMPA-cleared image-based IMR quantification tool in routine use there, and is the reporting quantitative rather than visual impression?
  3. For a patient with prior angiograms, can the assessment begin as an image review consultation before any repeat invasive procedure is proposed?
  4. What would the written quotation for the consultation, the procedure and the physiology measurement look like, separately itemised?

The third question is the one that saves most of the trouble. A reasonable second-opinion team will not jump to recatheterising you; it will look at your existing images, your symptom history and your non-invasive tests first, and only then decide whether microvascular physiology changes anything.

If the answer is yes and you want to proceed, the logistics are usually handled as a single coordinated sequence: records reviewed remotely, a consultation booked, the procedure scheduled separately once the team agrees it is indicated, and results discussed with a management plan at the end. OriEast can arrange the hospital appointment and interpreter support in Shanghai, review which departments have the relevant physiology capability through our hospital directory, and handle the practical side of travel and visa documentation. Start with a case evaluation so that a clinician-facing summary of your history is in front of the department before you commit to a date.

Cost, documents and honest expectations

The approval announcement contains no pricing, and we are not going to invent any. Invasive coronary physiology in China is quoted by the hospital as a combination of consultation fee, catheterisation procedure fee, consumables (sensor wire and vasodilator agent if the classic method is used) and imaging acquisition — and the total depends on the hospital's actual quotation for your specific case. Ask for the itemised figure in writing before travel, and ask separately whether any part is prepaid. For orientation on how Chinese cardiac care is generally structured and priced relative to other destinations, our complete guide to medical travel to China covers the framework; best international-standard hospitals in Shanghai covers the settings where English-language coordination is most realistic.

Bring more than you think you need: the original angiography DICOM files on disc or secure link (not only the PDF report), echocardiogram, ECGs including any recorded during symptoms, prior functional studies, laboratory results, a current medication list with doses, and a written symptom timeline in your own words. Incomplete imaging is the most common reason a second opinion has to be deferred, which costs you a trip you did not need to take.

If your work-up has not gone as far as catheterisation yet, a structured cardiovascular health assessment is a more proportionate first step than flying in for invasive testing, and results from either route can be brought back for review.

What this is not

Set this plainly, because it is where readers of a news-driven article get misled. IMR is a measurement, not a treatment. No approved software in this category opens an artery, and there is no basis for describing microvascular testing as a therapy. The point of quantifying resistance is that a documented number changes what your physician can reasonably do next: it moves the conversation from "your angiogram is normal, so nothing is wrong" to a specific diagnosis that has its own management pathway, usually built around risk-factor control and anti-anginal medication rather than stenting.

A test result is not a prescription. Any treatment plan has to be set by a licensed physician who has examined you in person and reviewed your complete history — including whether invasive testing is advisable for you at all. And none of this displaces emergency judgement: chest pain at rest that is new, prolonged, severe or accompanied by breathlessness, sweating or faintness needs emergency care where you are, immediately, not an international appointment.

The most useful thing a small regulatory announcement like this one can do for a patient is make a question answerable. If you have been told your arteries are clear and you still cannot do what you used to do, "does this centre measure IMR, and what was my value?" is a fair, checkable, technical question — and the right place to start is by sending us your records through the case evaluation form, or contacting our team directly to ask what a microvascular second opinion in China would involve for your situation.

Next step

If this topic is relevant to your treatment or travel plan, these pages are the best next place to continue.